Cardiotoxicity evaluation using magnetic resonance imaging in breast Cancer patients (CareBest): study protocol for a prospective trial

Yoo Jin Hong, Gun Min Kim, Kyunghwa Han, Pan Ki Kim, Su An Lee, Eunkyung An, Ji Yeon Lee, Hye-Jeong Lee, Jin Hur, Young Jin Kim, Min Jung Kim, Byoung Wook Choi, Yoo Jin Hong, Gun Min Kim, Kyunghwa Han, Pan Ki Kim, Su An Lee, Eunkyung An, Ji Yeon Lee, Hye-Jeong Lee, Jin Hur, Young Jin Kim, Min Jung Kim, Byoung Wook Choi

Abstract

Background: Cardiovascular disease is second only to cancer recurrence as a determinant of lifespan in cancer survivors, and cancer therapy-related cardiac dysfunction is a clinically important risk factor. We aim to investigate the use of cardiac magnetic resonance imaging (MRI) to evaluate early tissue changes and perform functional assessment of chemo- and radiation-induced cardiotoxicity and to identify MRI prognostic indicators of cardiotoxicity in breast cancer patients.

Methods: A 3-min cardiac imaging protocol will be added to the breast MRI examination to diagnose cardiotoxicity in breast cancer patients. Standardized MRI-based evaluation of breast cancer and the left ventricular myocardium will be performed at baseline and at 3, 6, and 12 months and 2 years or more after cancer treatment. We will analyze both ventricular volume and ejection fraction (EF), strain of left ventricle (LV), native T1, extracellular volume fraction (ECV), and T2 values acquired in the mid LV.

Discussion: The primary result of this study will be the comparison of the prognostic value of MRI parameters (native T1, ECV, both ventricular systolic function and LV strain) for cardiotoxicity. The endpoint is defined as the occurrence of a major adverse cardiac event (MACE). The secondary outcome will be an assessment of the temporal relationships between contractile dysfunction and microstructural injury over 4 years using MRI. This study will assess the usefulness of quantitative MRI to diagnose cardiotoxicity and will clarify the temporal relationships between contractile dysfunction and microstructural injury of the LV myocardium using MRI during breast cancer treatment.

Trial registration: The protocol was registered at clinicaltrials.gov (Clinical trial no. NCT03301389) on October 4, 2017.

Keywords: Cardiotoxicity; Extracellular volume fraction; Magnetic resonance imaging; Native T1; T1 mapping.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Study design Black circles indicate MRI scanning

References

    1. Lenneman CG, Sawyer DB. Cardio-oncology: an update on Cardiotoxicity of Cancer-related treatment. Circ Res. 2016;118(6):1008–1020. doi: 10.1161/CIRCRESAHA.115.303633.
    1. Bovelli D, Plataniotis G, Roila F, Group EGW Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncology. 2010;21(suppl_5):v277–vv82. doi: 10.1093/annonc/mdq200.
    1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220–241. doi: 10.3322/caac.21149.
    1. Trama A, Botta L, Foschi R, Ferrari A, Stiller C, Desandes E, et al. Survival of European adolescents and young adults diagnosed with cancer in 2000-07: population-based data from EUROCARE-5. Lancet Oncol. 2016;17(7):896–906. doi: 10.1016/S1470-2045(16)00162-5.
    1. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342(15):1077–1084. doi: 10.1056/NEJM200004133421502.
    1. Abdel-Qadir H, Austin PC, Lee DS, Amir E, Tu JV, Thavendiranathan P, et al. A population-based study of cardiovascular mortality following early-stage breast Cancer. JAMA Cardiol. 2017;2(1):88–93. doi: 10.1001/jamacardio.2016.3841.
    1. Colombo A, Sandri MT, Salvatici M, Cipolla CM, Cardinale D. Cardiac complications of chemotherapy: role of biomarkers. Curr Treat Options Cardiovasc Med. 2014;16(6):313. doi: 10.1007/s11936-014-0313-6.
    1. Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) Eur Heart J. 2016;37(36):2768–2801. doi: 10.1093/eurheartj/ehw211.
    1. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15(10):1063–1093. doi: 10.1093/ehjci/jeu192.
    1. Bloom MW, Hamo CE, Cardinale D, Ky B, Nohria A, Baer L, et al. Cancer therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging. Circ Heart Fail. 2016;9(1):e002661. doi: 10.1161/CIRCHEARTFAILURE.115.002661.
    1. Thavendiranathan P, Wintersperger BJ, Flamm SD, Marwick TH. Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review. Circ Cardiovasc Imag. 2013;6(6):1080–1091. doi: 10.1161/CIRCIMAGING.113.000899.
    1. Hong YJ, Park HS, Park JK, Han K, Park CH, Kim TK, et al. Early detection and serial monitoring of Anthracycline-induced Cardiotoxicity using T1-mapping cardiac magnetic resonance imaging: an animal study. Sci Rep. 2017;7(1):2663. doi: 10.1038/s41598-017-02627-x.
    1. Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI) J Cardiovasc Magn Reson. 2017;19(1):75. doi: 10.1186/s12968-017-0389-8.
    1. Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162(1):W1–73. doi: 10.7326/M14-0698.
    1. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–845. doi: 10.2307/2531595.
    1. Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) Eur J Heart Fail. 2017;19(1):9–42. doi: 10.1002/ejhf.654.
    1. Hamo CE, Bloom MW, Cardinale D, Ky B, Nohria A, Baer L, et al. Cancer therapy-related cardiac dysfunction and heart failure: part 2: prevention, treatment, guidelines, and future directions. Circ Heart Fail. 2016;9(2):e002843. doi: 10.1161/CIRCHEARTFAILURE.115.002843.
    1. Armenian SH, Hudson MM, Mulder RL, Chen MH, Constine LS, Dwyer M, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the international late effects of childhood Cancer guideline harmonization group. Lancet Oncol. 2015;16(3):e123–e136. doi: 10.1016/S1470-2045(14)70409-7.
    1. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23(Suppl 7):vii155–vii166. doi: 10.1093/annonc/mds293.
    1. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981–1988. doi: 10.1161/CIRCULATIONAHA.114.013777.
    1. Jordan JH, Todd RM, Vasu S, Hundley WG. Cardiovascular magnetic resonance in the oncology patient. JACC Cardiovasc Imaging. 2018;11(8):1150–1172. doi: 10.1016/j.jcmg.2018.06.004.
    1. Galan-Arriola C, Lobo M, Vilchez-Tschischke JP, Lopez GJ, de Molina-Iracheta A, Perez-Martinez C, et al. Serial magnetic resonance imaging to identify early stages of Anthracycline-induced Cardiotoxicity. J Am Coll Cardiol. 2019;73(7):779–791. doi: 10.1016/j.jacc.2018.11.046.
    1. Ferreira de Souza T, Quinaglia ACST, Osorio Costa F, Shah R, Neilan TG, Velloso L, et al. Anthracycline therapy is associated with Cardiomyocyte atrophy and preclinical manifestations of heart disease. JACC Cardiovasc Imaging. 2018;11(8):1045–1055. doi: 10.1016/j.jcmg.2018.05.012.
    1. Gong IY, Ong G, Brezden-Masley C, Dhir V, Deva DP, Chan KKW, et al. Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal study. Int J Cardiovasc Imag. 2019;35(4):653–662. doi: 10.1007/s10554-018-1482-2.
    1. Barthur A, Brezden-Masley C, Connelly KA, Dhir V, Chan KK, Haq R, et al. Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study. J Cardiovasc Magn Reson. 2017;19(1):44. doi: 10.1186/s12968-017-0356-4.
    1. Ong G, Brezden-Masley C, Dhir V, Deva DP, Chan KKW, Chow CM, et al. Myocardial strain imaging by cardiac magnetic resonance for detection of subclinical myocardial dysfunction in breast cancer patients receiving trastuzumab and chemotherapy. Int J Cardiol. 2018;261:228–233. doi: 10.1016/j.ijcard.2018.03.041.
    1. Plana JC, Thavendiranathan P, Bucciarelli-Ducci C, Lancellotti P. Multi-modality imaging in the assessment of cardiovascular toxicity in the Cancer patient. JACC Cardiovasc Imaging. 2018;11(8):1173–1186. doi: 10.1016/j.jcmg.2018.06.003.
    1. Henry ML, Niu J, Zhang N, Giordano SH, Chavez-MacGregor M. Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast Cancer patients. JACC Cardiovasc Imaging. 2018;11(8):1084–1093. doi: 10.1016/j.jcmg.2018.06.005.
    1. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol. 2001;2(3):133–140. doi: 10.1016/S1470-2045(00)00254-0.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj